68Ga-RYZ-811

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug Name68Ga-RYZ-811
Drug Alias NameRYZ-811RYZ811(68Ga)68Ga-Ga-RYZ-GPC368Ga-GPC368Ga-RYZ-811
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5] 
Mechanisms of ActionAnti-Glypican-3Positron-emission tomography enhancersRadionuclide imaging enhancers
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPeptiDream IncRayzeBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream IncRayzeBio Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A